RightFit
RecruitingNot applicable

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer

Elucidating the Metabolic Impact of Isocaloric, Controlled, Mediterranean-Type Diets in Treatment-Naïve Men With Prostate Cancer on Active Surveillance (DINE Study)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The purpose of this study is to examine the impact of Mediterranean-type diets on the metabolism of men with localized prostate cancer. The optimal diet for men with a suspected diagnosis of Prostate Cancer (PCa) is currently unknown. More specifically, the suggested benefits of low carbohydrate and low fat diets in PCa are not determined.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * Males ≥18 years old * High suspicion of prostate cancer (PCa) per urologist's clinical evaluation * BMI \>18.5 * No prior PCa diagnosis or hormonal therapy (-ies) * Ability to read, write, speak, and understand English * Ability to provide informed consent * Candidate for and elects active surveillance (AS) if diagnostic biopsy is positive * Willingness to consume provided dietary interventions * Adequate organ and marrow function: White blood cell count (WBC) ≥2,500/mcL, Absolute neutrophil count (ANC) ≥1,500/mcL, Platelets ≥100,000/mcL, Hemoglobin ≥9 g/dL (transfusions permitted), Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN) (for subjects with Gilbert's disease ≤3.0 mg/dL), Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x institutional ULN, Creatinine clearance ≥51 ml/min as defined by Cockcroft-Gault equation Exclusion Criteria: * Currently consuming a Mediterranean, lower carbohydrate, ketogenic, vegan, vegetarian, high fiber diet (14g fiber \> per 1,000 Calories) and/or any supplements (including herbal), vitamins, minerals, that would interfere with diets being tested in the study as determined by dietitian and/or investigators. * Previous intolerability to fiber-rich diets * Colitis, Irritable Bowel Syndrome, or other gastrointestinal condition per clinician discretion * Unwilling to undergo transperineal PCa biopsies * Food allergies or other major dietary restrictions * Receiving active medical treatment for Type I or Type II diabetes mellitus * Prior antibiotic usage (i.e. within last 30 days) at time of consent * Recent weight loss (both intentional and unintentional) as defined by 5%+ body weight in the last 30 days * Undergone any type of weight loss surgery * Any medical contraindications as determined by investigators * High risk as defined by PSA≥20 and/or PI-RADS 5 lesion as per clinician evaluation * History of diabetic ketoacidosis * Gout * Patients that are immunosuppressed (transplant history, on immunosuppression, etc.) as per clinician discretion * Recent (within last 30 days) device implant/joint requiring antibiotics as per clinician determination * Prior history of prostate biopsy infection * Uncontrolled hypertension as defined by blood pressure greater than 140/80 (with or without medication) * Gallbladder removed or plan to remove per clinician evaluation * Other malignancies actively receiving systemic treatment as per clinician evaluation

Study sites (1)

OH